FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109800972> ?p ?o ?g. }

• W3109800972 endingPage "207" @default.
• W3109800972 startingPage "201" @default.
• W3109800972 abstract "Introduction For patients with inflammatory bowel diseases, switching from infliximab originator to biosimilars is effective and safe. Few data on single switch have been published, and data on multiple switches of different infliximab are unavailable. Methods A retrospective analysis of patients who switched from CT-P13 to SB2, and of those with multiple switches among different infliximab compounds was conducted. Clinical activity, C reactive protein (CRP), adverse events (AE) and loss of response (LOR) were recorded. Results Thirty-six patients (26 males, 14 Crohn’s disease and 22 ulcerative colitis) were enrolled and followed up for >6 months. All patients switched from CT-P13 to SB2; 12 of them (33.3%) had already switched from reference Infliximab to CT-P13, and for the remaining patients CT-P13 was the first infliximab. The clinical remission rate six months before and three months after SB2-switch was the same (58.3%) and the rate of mild activity varied from 27.8 to 33.3% ( P = 0.68); the percentage of patients with normal CRP values passed from 94.4 to 91.7% ( P = 1). Two patients (5.5%) had AE and 11 (30.5%) a LOR. At univariate analysis, patients with a single switch had a non-significant risk of LOR during SB2 [odds ratio (OR) = 7.86; 95% confidence interval (CI) 0.87–71, P = 0.06]. SB2-LOR was associated with previous AE under CT-P13 (OR = 9.1, 95% CI 0.82–100, P = 0.07). None of such factors was significant at multivariate analysis. Conclusion Switching from CT-P13 to SB2 seems to be safe and effective either in patients with a single than in those with multiple switches." @default.
• W3109800972 created "2020-12-07" @default.
• W3109800972 creator A5005051512 @default.
• W3109800972 creator A5015267957 @default.
• W3109800972 creator A5020815682 @default.
• W3109800972 creator A5027627732 @default.
• W3109800972 creator A5030446175 @default.
• W3109800972 creator A5034894691 @default.
• W3109800972 creator A5040818753 @default.
• W3109800972 creator A5042138127 @default.
• W3109800972 creator A5048061499 @default.
• W3109800972 creator A5059256208 @default.
• W3109800972 creator A5077581417 @default.
• W3109800972 date "2020-11-19" @default.
• W3109800972 modified "2023-10-14" @default.
• W3109800972 title "Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease" @default.
• W3109800972 cites W1504996215 @default.
• W3109800972 cites W1560551965 @default.
• W3109800972 cites W1967542932 @default.
• W3109800972 cites W2051028531 @default.
• W3109800972 cites W2073123864 @default.
• W3109800972 cites W2102013054 @default.
• W3109800972 cites W2139133180 @default.
• W3109800972 cites W2171297959 @default.
• W3109800972 cites W2188268681 @default.
• W3109800972 cites W2321433516 @default.
• W3109800972 cites W2560455300 @default.
• W3109800972 cites W2578994901 @default.
• W3109800972 cites W2579963361 @default.
• W3109800972 cites W2606337392 @default.
• W3109800972 cites W2613299853 @default.
• W3109800972 cites W2743976598 @default.
• W3109800972 cites W2754846891 @default.
• W3109800972 cites W2767179430 @default.
• W3109800972 cites W2792476042 @default.
• W3109800972 cites W2908133328 @default.
• W3109800972 cites W2915543214 @default.
• W3109800972 cites W2938260764 @default.
• W3109800972 cites W4211167126 @default.
• W3109800972 doi "https://doi.org/10.1097/meg.0000000000001988" @default.
• W3109800972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33369956" @default.
• W3109800972 hasPublicationYear "2020" @default.
• W3109800972 type Work @default.
• W3109800972 sameAs 3109800972 @default.
• W3109800972 citedByCount "7" @default.
• W3109800972 countsByYear W31098009722021 @default.
• W3109800972 countsByYear W31098009722022 @default.
• W3109800972 countsByYear W31098009722023 @default.
• W3109800972 crossrefType "journal-article" @default.
• W3109800972 hasAuthorship W3109800972A5005051512 @default.
• W3109800972 hasAuthorship W3109800972A5015267957 @default.
• W3109800972 hasAuthorship W3109800972A5020815682 @default.
• W3109800972 hasAuthorship W3109800972A5027627732 @default.
• W3109800972 hasAuthorship W3109800972A5030446175 @default.
• W3109800972 hasAuthorship W3109800972A5034894691 @default.
• W3109800972 hasAuthorship W3109800972A5040818753 @default.
• W3109800972 hasAuthorship W3109800972A5042138127 @default.
• W3109800972 hasAuthorship W3109800972A5048061499 @default.
• W3109800972 hasAuthorship W3109800972A5059256208 @default.
• W3109800972 hasAuthorship W3109800972A5077581417 @default.
• W3109800972 hasConcept C126322002 @default.
• W3109800972 hasConcept C141071460 @default.
• W3109800972 hasConcept C144301174 @default.
• W3109800972 hasConcept C156957248 @default.
• W3109800972 hasConcept C167135981 @default.
• W3109800972 hasConcept C197934379 @default.
• W3109800972 hasConcept C2777138892 @default.
• W3109800972 hasConcept C2778260677 @default.
• W3109800972 hasConcept C2779134260 @default.
• W3109800972 hasConcept C2780479503 @default.
• W3109800972 hasConcept C38180746 @default.
• W3109800972 hasConcept C44249647 @default.
• W3109800972 hasConcept C59491497 @default.
• W3109800972 hasConcept C71924100 @default.
• W3109800972 hasConcept C90924648 @default.
• W3109800972 hasConceptScore W3109800972C126322002 @default.
• W3109800972 hasConceptScore W3109800972C141071460 @default.
• W3109800972 hasConceptScore W3109800972C144301174 @default.
• W3109800972 hasConceptScore W3109800972C156957248 @default.
• W3109800972 hasConceptScore W3109800972C167135981 @default.
• W3109800972 hasConceptScore W3109800972C197934379 @default.
• W3109800972 hasConceptScore W3109800972C2777138892 @default.
• W3109800972 hasConceptScore W3109800972C2778260677 @default.
• W3109800972 hasConceptScore W3109800972C2779134260 @default.
• W3109800972 hasConceptScore W3109800972C2780479503 @default.
• W3109800972 hasConceptScore W3109800972C38180746 @default.
• W3109800972 hasConceptScore W3109800972C44249647 @default.
• W3109800972 hasConceptScore W3109800972C59491497 @default.
• W3109800972 hasConceptScore W3109800972C71924100 @default.
• W3109800972 hasConceptScore W3109800972C90924648 @default.
• W3109800972 hasIssue "2" @default.
• W3109800972 hasLocation W31098009721 @default.
• W3109800972 hasOpenAccess W3109800972 @default.
• W3109800972 hasPrimaryLocation W31098009721 @default.
• W3109800972 hasRelatedWork W2339588938 @default.
• W3109800972 hasRelatedWork W2541335332 @default.
• W3109800972 hasRelatedWork W2587460980 @default.
• W3109800972 hasRelatedWork W2972178939 @default.

• next